Efficacy of Ritlecitinib (PF-06651600) in Patients With Alopecia Totalis and Alopecia Universalis: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

Main Article Content

Xingqi Zhang
The First Affiliated Hospital, Sun Yat-sen University

Nina Magnolo
University Hospital Münster Department of Dermatology

Masato Mizuashi
Tohoku University Graduate School of Medicine

Natasha Mesinkovska
University of California, Irvine, School of Medicine

Jerry Shapiro
New York University Grossman School of Medicine

Fan Zhang
Pfizer Inc

Urs Kerkmann
Pfizer Pharma GmbH

Ernest Law
Pfizer Inc

Robert Wolk
Pfizer Inc

Gregor Schaefer
Pfizer Pharma GmbH

Keywords

ritlecitinib, efficacy, alopecia totalis, alopecia universalis, ALLEGRO, clinical trial

References

1. Islam N, et al. Autoimmun Rev. 2015;14:81-89

2. Delamere FM, et al. Cochrane Database Syst Rev. 2008;16:CD004413

3. Olsen EA, et al. J Am Acad Dermatol. 2018;79:470-478

4. King B, et al. Presented at: EADV 2021

Article Sidebar

Poster PDF
Published
Nov 16, 2022
DOI https://doi.org/10.25251/skin.6.supp.102

Article Details

How to Cite
Zhang, X., Magnolo, N., Mizuashi, M., Mesinkovska, N., Shapiro, J., Zhang, F., Kerkmann, U., Law, E., Wolk, R., & Schaefer, G. (2022). Efficacy of Ritlecitinib (PF-06651600) in Patients With Alopecia Totalis and Alopecia Universalis: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study. SKIN The Journal of Cutaneous Medicine, 6(6), s102. https://doi.org/10.25251/skin.6.supp.102
Issue
Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Section
Alopecia
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 > >>